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A B S T R A C T
Background: Nevoid basal cell carcinoma syndrome (NBCCS) is an autosomal dominant disorder mainly
caused by heterozygous mutations of PTCH1. In addition to characteristic clinical features, detection of a
mutation in causative genes is reliable for the diagnosis of NBCCS; however, no mutations have been
identiﬁed in some patients using conventional methods.
Objective: To improve the method for the molecular diagnosis of NBCCS.
Methods: We performed targeted exome sequencing (TES) analysis using a multi-gene panel, including
PTCH1, PTCH2, SUFU, and other sonic hedgehog signaling pathway-related genes, based on next-
generation sequencing (NGS) technology in 8 cases in whom possible causative mutations were not
detected by previously performed conventional analysis and 2 recent cases of NBCCS. Subsequent
analysis of gross deletion within or around PTCH1 detected by TES was performed using chromosomal
microarray (CMA).
Results: Through TES analysis, speciﬁc single nucleotide variants or small indels of PTCH1 causing
inferred amino acid changes were identiﬁed in 2 novel cases and 2 undiagnosed cases, whereas gross
deletions within or around PTCH1, which are validated by CMA, were found in 3 undiagnosed cases.
However, no mutations were detected even by TES in 3 cases. Among 3 cases with gross deletions of
PTCH1, deletions containing the entire PTCH1 and additional neighboring genes were detected in 2 cases,
one of which exhibited atypical clinical features, such as severe mental retardation, likely associated
with genes located within the 4.3 Mb deleted region, especially.
Conclusion: TES-based simultaneous evaluation of sequences and copy number status in all targeted
coding exons by NGS is likely to be more useful for the molecular diagnosis of NBCCS than conventional
methods. CMA is recommended as a subsequent analysis for validation and detailed mapping of deleted
regions, which may explain the atypical clinical features of NBCCS cases.
 2017 Japanese Society for Investigative Dermatology. Published by Elsevier Ireland Ltd. All rights
reserved.Abbreviations: NBCCS, nevoid basal cell carcinoma syndrome; KCOT, keratocystic
odontogenic tumor; Shh, sonic hedgehog; PCR–SSCP, polymerase chain reaction–
single strand conformation polymorphism; CNA, copy number alteration; NGS,
next-generation sequencing; SNV, single nucleotide variant; indel, insertion/
deletion; TES, targeted exome sequencing; CMA, chromosomal microarray; HGMD,
human genome mutation database; SNP, single-nucleotide polymorphism; ChAS,
Chromosome Analysis Suite; OMIM, Online Mendelian Inheritance in Man.
* Corresponding author. Tel.: +81 886 33 7154; fax: +81 886 32 0434.
E-mail address: kubo@tokushima-u.ac.jp (Y. Kubo).
http://dx.doi.org/10.1016/j.jdermsci.2017.02.282
0923-1811/ 2017 Japanese Society for Investigative Dermatology. Published by Elsev1. Introduction
Nevoid basal cell carcinoma syndrome (NBCCS; MIM# 109400),
also known as Gorlin syndrome, is an autosomal dominant
disorder exhibiting multiple BCCs, palmoplantar pits, keratocystic
odontogenic tumors (KCOTs), calciﬁcation of the falx cerebri, and
skeletal abnormalities [1]. PTCH1 (MIM# 601309), mapped to
9q22.32 and consisting of 23 exons encoding 1447 amino acids, has
been identiﬁed as a main causative gene for NBCCS [2,3]. Theier Ireland Ltd. All rights reserved.
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activation of the Shh pathway due to inactivation of PTCH1
protein may be relevant to NBCCS phenotypes [2].
Although we had performed polymerase chain reaction–single
strand conformation polymorphism (PCR–SSCP) analysis and
Sanger sequencing in 20 cases of NBCCS following the previous
report [4], we failed to detect any PTCH1mutations in 8 of 20 cases
(40%) of NBCCS by the analyses. As the detection rates of germline
PTCH1mutations in cases of NBCCS were reported to be 40–75% by
conventional methods, such as PCR–SSCP analysis, PCR-based direct
sequencing of all exons, or denaturing high performance liquid
chromatography [5–7], our detection rate of 60% was similar to
those results. This failure to detect mutations may be due to copy
number alterations (CNAs) of the regions over one exon of PTCH1
[8,9], the presence of mutations located outside exons and exon-
intron boundaries of PTCH1, such as mutations within introns or
regulatory regions of PTCH1, or mutations in other candidate genes
associated with the Shh pathway, such as PTCH2, SUFU, SHH, GLI1/2/
3, SMO, HHIP, KIF7, and STK36. Among them, PTCH2 (MIM# 603673)
and SUFU (MIM# 607035) have been identiﬁed as causative genes
with heterozygous mutations in rare cases of NBCCS [10–12].
Recently, next-generation sequencing (NGS) has been adopted
in clinical testing for patientswith congenital diseases suspected to
be genetic in origin including NBCCS, because single-nucleotide
variations (SNVs) and small insertions/deletions (indels) as well as
gross CNAs involved in a defect of disease-causing genes can be
simultaneously screened using whole exome sequencing or
targeted exome sequencing (TES) in a time- and cost-effective
manner [9]. In this study, we performed a comprehensive TES-
based genetic analysis using a multi-gene panel, including PTCH1,
PTCH2, SUFU, and other shh-related genes except SMO and STK36 in
8 cases with nomutations detected by previous PCR–SSCP analysis
and 2 recently enrolled cases of NBCCS (Fig. 1), gross deletions
detected in PTCH1 by TESwere examined in detail by chromosomal
microarray (CMA) analysis.
2. Materials and methods
2.1. Cases analyzed by TES analysis
We analyzed 10 Japanese cases with a clinical diagnosis of
NBCCS based on the presence of diagnostic criteria of Kimonis[(Fig._1)TD$FIG]
Fig. 1. Flow chart(Table 1, Supplementary Fig. S1) [13]. In 8 cases, no PTCH1
mutations were detected by our previous PCR–SSCP analysis
(Fig. 1). In the remaining 2 recent new cases, we performed TES
analysis without PCR–SSCP analysis in advance. The molecular
diagnosis was performed using genomic DNA extracted from
the patient’s whole blood after obtaining informed consent. This
study was approved by the ethical committees of Tokushima
University.
2.2. TES by NGS and data analyses
Weused aMiSeq bench-top sequencer (Illumina, San Diego, CA,
USA) to perform NGS with a TruSight One Sequencing Panel
(Illumina), which provides for the simultaneous targeted sequenc-
ing of the exon regions of 4813 clinically relevant genes. The
alignments of sequencing reads to the human reference genome
(GRCh37/hg19), duplicate read removal, local realignment around
indels, base quality score recalibration, variant calling and
annotation were performed as previously described [14]. To
identify single nucleotide variants (SNVs), we excluded sequence
variants with minor allele frequencies (>0.01) included in various
human genome variation databases, as previously described [14]
and an integrative Japanese Genome Variation Database (iJGVD,
https://ijgvd.megabank.tohoku.ac.jp/) [15]. To complement the
SNVs and indel analyses, detection of CNAs using TES data with a
resolution of a single exon to several exons, depending on the size
of exons, was performed using DNAcopy (R/Bioconductor; http://
bioconductor.org) [16] and eXome-Hidden Markov Model v1.0
(XHMM, https://atgu.mgh.harvard.edu/xhmm/) as previously
described [17].
Candidates for pathogenic variants were conﬁrmed by Sanger
sequencing. The pathogenicity of missense variants was assessed
using tools for prediction of possible impact of amino acid
substitution on the structure and function of human protein such
as MutationTaster (http://www.mutationtaster.org/index.html),
PolyPhen-2 version 2.2.2r398 (http://genetics.bwh.harvard.edu/
pph2/index.shtml), and PROVEAN tool (http://provean.jcvi.org.).
Identiﬁed alterations were also evaluated by comparison with
known alterations reported in mutation databases such as the
Human Genome Mutation Database (HGMD) professional 2016.1
(http://www.hgmd.cf.ac.uk/ac/index.php) and ClinVar (http://
www.ncbi.nlm.gov/clinvar).of this study.
Table 1
Clinical features of NBCCS cases in this study.
Case no. Age (yr) Gender Major criteria Minor criteria Other clinical
features
BCC Multiple
KCOTs
Palmo-
plantar pits
Calciﬁcation
of falx cerebri
Rib
anomalies
Family
history
Numbers Locations
1 31 M No Yes Yes Yes No No No No
2 21 F 3 Face Yes Yes Yes No No No West syndrome,
MR, hydro-cephalus,
autism
3 60 F Dozens Head, face Yes Yes Yes No Yes (son) Coarse face,
scoliosis
No
4 64 M 16 Face, abdomen,
back
Yes Yes Yes No No No No
5 17 F No Yes Yes Yes Yes No No No
6 31 F 1 Forehead No Yes Yes No No Cleft palate,
coarse face
Hydro-cephalus
7 62 F 6 Forehead, axilla,
upper chest
No Yes Yes No Yes (son,
daughter)
No No
8 41 F No Yes No Yes No No Macro-cephaly,
frontal bossing,
hyper-telorism
No
9 35 M 1 Nose Yes No Yes No No Frontal bossing,
hyper-telorism
No
10 21 M No Yes No NT No No Hyper-telorism Skin cysts
BCC, basal cell carcinoma; KCOT, keratocystic odontogenic tumor; MR, mental retardation; NT, not tested.
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CNA validation and detailed mapping of altered regions were
performed using the CytoScan HD array platform (Affymetrix,
Santa Clara, CA, USA), which provides 750,000 polymorphic
(single-nucleotide polymorphism, SNP) and 1950,000 non-poly-
morphic (CNA) markers as described previously [9,17]. The raw
data were analyzed using Affymetrix Chromosome Analysis Suite
(ChAS) Software and the output data were interpreted with the
UCSC Genome Browser (http://genome.ucsc.edu). The disease-
related genes were selected based on the information from Online
Mendelian Inheritance in Man (OMIM, http://www.omim.org/).Table 2
Results of targeted exome sequencing analysis.
Case no. PTCH1
mutation
detected by
PCR–SSCP
analysis
Altered
gene(s)
detected
by TES
Mutation of PTCH1
Type Nucleic acid change Amin
chan
1 No No
2 No 50 genes
including
PTCH1
Gross deletion
3 No PTCH1 Nonsense c.2198C>G p.S73
4 No No
5 No PTCH1 Gross deletion
6 No No
7 No PTCH1 Missense c.1313G>T p.S43
8 No 25 genes
including
PTCH1
Gross deletion
9 NT PTCH1 2-bp deletion
and 8-bp insertion
c.3487_
3488delinsAATGGGCC
p.G1
10 NT PTCH1 Frame-shift c.1670_1671del p.T5
PCR–SSCP, polymerase chain reaction–single strand conformation polymorphism; NT,3. Results
All 10 cases satisﬁed clinical diagnostic criteria of NBCCS
(Table 1). Out of 10 cases, speciﬁc SNVs or small indels of PTCH1
causing inferred amino acid changes were identiﬁed in 4 cases,
whereas CNAs within or around PTCH1 were found in 3 cases
(Fig. 1, Table 2). SNVs or CNAs were detected by TES in 5 of 8 cases,
in which possible causative SNVs were not detected by previous
PCR–SSCP analysis (Fig. 1, Table 2). In the remaining 3 cases,
however, no possible disease-causing genetic alterations were
detected in PTCH1, PTCH2, SUFU, and other shh-related genes
except SMO and STK36, which are not included in TruSight Oneo acid
ge
Exon Mutation-
Taster
prediction
(score)
PolyPhen-2
prediction
(score)
PROVEAN
tool
prediction
(score)
Reported as
pathogenic
alteration
All No
3X 14 Disease
causing
(1)
NA Neutral
(2.287)
No
12–15 No
8I 9 Disease
causing (1)
Probably
damaging
(0.996)
Deleterious
(5.048)
No
All No
163delinsNGP 21 Disease
causing (0.999)
NA Deleterious
(12.476)
No
57Sfs*69 12 Disease
causing (1)
NA NA Takahashi
et al. [18]
not tested; NA, not available.
Y. Matsudate et al. / Journal of Dermatological Science 86 (2017) 206–211 209sequencing panel, even though these 3 cases satisﬁed the same
diagnostic criteria as the other 7 cases (Table 1).
3.1. Causative SNVs and indels identiﬁed in cases with NBCCS by TES
3.1.1. Case 3
In case 3, we identiﬁed a nonsensemutation in PTCH1 (p.S733X)
caused by a 1 base substitution at nucleotide 2198, which was
predicted to be a loss-of-function mutation, likely leading to an
aberrant mRNA targeted for degradation via nonsense-mediated
decay (NMD) or resulting in a truncated protein.
3.1.2. Case 7
In case 7, we identiﬁed a missense mutation in PTCH1 (p.S438I)
caused by a 1 base substitution at nucleotide 1313 in exon 9. This
mutation was predicted to be ‘‘deleterious’’ and ‘‘damaging’’ by
PROVEAN tool and PolyPhen-2, respectively. The same alterationwas
detected in the affected daughter, although genetic analysis has
never been performed in the affected son (Supplementary Fig. S1).
Therefore, we concluded this alteration to be responsible for NBCCS,
even though thismutationhasnot been reported inHGMDorClinVar.
3.1.3. Case 9
In case 9, we identiﬁed an in-frame indel, a 2-bp deletion and 8-
bp insertion (c.3487_3488delinsAATGGGCC) in exon 21, resulting
in the inclusion of two amino acids (p.G1163delinsNGP)within the
transmembrane domain. This mutation was predicted as ‘‘delete-
rious’’ by PROVEAN tool. Therefore, we concluded this alteration to
be responsible for NBCCS, even though this mutation has not been
reported in HGMD or ClinVar.
3.1.4. Case 10
In case 10, we identiﬁed a possibly deleterious frameshift
mutation (p.T557Sfs*69) creating a new stop codon at codon
625 by a 2-bp deletion at nucleotides 1670-1671 in exon 12. As this
mutation was previously reported to be causative for NBCCS by
Takahashi et al. [18], we concluded this alteration to be responsible
for NBCCS.
3.2. Causative CNAs identiﬁed in cases with NBCCS by TES
In 3 cases, we were unable to identify any causative SNVs or
indels within the possible target genes, but rather detected entire
[(Fig._2)TD$FIG]
Fig. 2. Graphical representation of DNA copy number alterationor intragenic PTCH1 deletions resulting in loss-of-function of this
gene by TES analysis (Table 2, Fig. 2). All these deletions failed to be
detected by previous PCR–SSCP analysis. As TES is able to detect
CNAs only on targeted exons and unable to correctly determine an
altered copy number, CMA analysis was subsequently performed
to validate these deletions and to determine copy number and
detailed genomic location of the deleted regions (Fig. 3A–C).
3.2.1. Case 2 and case 8
In cases 2 and 8, we detected gross hemizygous deletions
including the entire PTCH1 gene. In case 2, we identiﬁed an
approximately 4.06 Mb deletion (chr9: 97,848,293–101,911,452)
containing 90 target exons including all exons of PTCH1 by TES.
Hemizygous deletion was conﬁrmed by CMA, and the precise size
of the deletion determined by CMA was approximately 4.3 Mb
(chr9:97,637,037–101,936,873) containing 50 RefSeq genes
(24 disease-related genes) from C9orf3 to TGFBR1 (Fig. 3A). In
case 8, we identiﬁed an approximately 1.22 Mb deletion
(chr9:97,848,293–99,064,223) containing 50 target exons includ-
ing all exons of PTCH1 by TES. Hemizygous deletion was conﬁrmed
by CMA, and the precise size of the deletion determined by CMA
was approximately 2.22 Mb (chr9:97,470,295–99,685,607) con-
taining 25 RefSeq genes (9 disease-related genes) from C9orf3 to
LOC441454 (Fig. 3B). These alterations have not been reported in
HGMD or ClinVar. Array-based karyotype results of cases 2 and
8 were arr[hg19] 9q22.32(97,637,037_101,936,873)  1 and
arr[hg19] 9q22.32(97,470,295_99,685,607)  1, respectively.
3.2.2. Case 5
In case 5, we detected an approximately 8.92 kb intragenic
deletion of PTCH1 from exon 12 to exon 15 (chr9:98,229,388–
98,238,306) by TES. Hemizygous deletion within PTCH1 of
approximately 7.93 kb (chr9: 98,227,309–98,235,234) was con-
ﬁrmed by CMA. Array-based karyotype results of case 5 was
arr[hg19] 9q22.32(98,227,309_98,235,234)  1, although the lo-
cation and size of the deleted region may be underestimated or
overestimated due to uneven coverage of probes on CMA (Fig. 3C).
These alterations have not been reported in HGMD or ClinVar.
4. Discussion
In this study, we applied TES using a TruSight One Sequencing
Panel based on NGS technology to simultaneously investigate thes in PTCH1 regions by targeted exome sequencing analysis.
[(Fig._3)TD$FIG]
Fig. 3. Image of deleted regions detected by chromosomal microarray analysis. (A) An approximately 4.3 Mb deletion containing genes from C9orf3 to TGFBR1, including full-
length PTCH1, was detected in case 2. (B) An approximately 2.22 Mb deletion containing genes from C9orf3 to LOC441454, including full-length PTCH1, was detected in case 8.
(C) The deletion size was approximately 7.93 kb within PTCH1 in case 5.
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causing genes, including known three causative genes, PTCH1,
PTCH2, and SUFU, in 10 cases with a clinical diagnosis of NBCCS. In
2 cases (cases 9 and 10) that have not been analyzed by PCR–SSCP
analysis, we detected small PTCH1 indels. In 8 cases (cases 1–8)
wherewewere not able to detect any PTCH1mutations by previous
PCR–SSCP analysis and Sanger sequencing, PTCH1 small deletions/
insertionswere identiﬁed by NGS and Sanger sequencing in 2 cases
(cases 3 and 7). This is because the causative exons have not been
checked due to no obvious pattern differences by PCR–SSCP
analysis. In 3 cases (cases 2, 5 and 8), we identiﬁed gross deletions,
which were not detected by conventional methods. However, no
mutation was detected within possible disease-causing genes in
shh pathway even by TES analysis in 3 cases (cases 1, 4 and 6),
although SMO and STK36, which have never been identiﬁed as
causative genes for NBCCS, are not included in our sequencingpanel. In these cases, mutations may exist outside of the analyzed
regions such as those within introns or regulatory regions of the
candidate genes. In addition, it is difﬁcult to exclude the possibility
of somatic mosaicism occurred in causative genes, although only
one case of possible type 2 mosaicism of PTCH1 in NBCCS has been
reported [19] and none of our mutation-negative cases showed
signs of segmental distribution of BCCs, pits, and so on. Further
examinations using additional techniques, such as whole genome
sequencing and ultra deep sequencing or digital PCR, are needed to
detect variations in these mutation-negative cases.
Although there was no signiﬁcant difference in the major
clinical features of NBCCS among the 10 cases, many atypical
clinical features were observed in case 2 out of 2 cases (cases 2 and
8) in which entire PTCH1 deletions were detected. The clinical
features of case 2 included severe mental retardation, WEST
syndrome (epilepsy), autism, hydrocephalus, hypotonia, inguinal
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strabismus. On the other hand, case 8 presented typical clinical
features of NBCCS and no atypical phenotype.
As C9orf3 at the proximal site of the deletion was common to
both case 2 and case 8, the distal region of the deletion that
consisted of approximately 2.25 Mb (chr9: 99,685,608–
101,936,873) containing 25 RefSeq genes (15 disease-related
genes) from NUTM2G to TGFBR1 may have contributed to the
development of the atypical phenotype only observed in case
2. Similar phenotypes with interstitial 9q22.3 microdeletion have
been reported as microdeletion 9q22.3 syndrome [20–22]. Among
them, 2 cases reported by Redon et al. [20] closely resembled case
2 in terms of both clinical features and deletion sites, suggesting
that genes involved in the genotype-phenotype correlation in
these two reported cases and case 2 locate within this 2.25 Mb
deleted region.
Among 25 RefSeq genes (15 OMIM genes) from NUTM2G to
TGFBR1, we take note of TGFBR1 with particular interest. TGFBR1
encodes the type 1 transforming growth factor beta (TGF-b)
receptor. TGF-b superfamily signaling pathways are ubiquitous
and essential regulators of cellular and physiological processes
[23]. Heterozygous loss-of-function mutations in TGFBR1 are
reported to cause multiple developmental anomalies referred to
as Loeys–Dietz syndrome [24]. This syndrome exhibits widespread
perturbations in cardiovascular, craniofacial, neurocongnitive and
skeletal development, although cases with this syndrome having
TGFBR1 deletion have not developed aortic aneurysms to date,
suggesting that at least some mutant protein needs to be present
for cardiovascular features of this disease [24–26]. Scoliosis and
strabismus are frequently observed in this disease, and mental
retardation (developmental delay) and hydrocephalus are ob-
served in a minority of affected individuals [26]. Although a rare
case of NBCCS with autism due to a deletion of 22 base pairs in
PTCH1 has also been reported [27] andHABP4, which locateswithin
the commonly deleted region between cases 2 and 8 (Fig. 3), has
been proposed as a cause ofmental retardation in a NBCCS patients
[9], we speculated that heterozygous loss-of-function in both
PTCH1 and TGFBR1 may contribute to some of atypical clinical
features in NBCCS observed in case 2.
In conclusion, TES analysis using NGS technology demonstrated
superior sensitivity compared with our previous methods in both
mutation and CNA detection of candidate disease-causing genes
for NBCCS. Therefore, TES-ﬁrst approach followed by CMA may be
cost- and time-effective for the molecular diagnosis of NBCCS.
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